# US 2018/0021265 A1 · Compositions and methods for nanoparticle-based drug delivery and imaging

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021265 A1
- Document ID: US20180021265A1
- Status: Published application
- Kind: A1
- Application number: 15/551,751
- Filed: 2016-02-17
- Published: 2018-01-25
- Earliest claimed: 2015-02-18
- Assignees: Memorial Sloan Kettering Cancer Center
- Applicants: Memorial Sloan Kettering Cancer Center
- Inventors: Jan GRIMM; Charalambos KAITTANIS; Travis M. SHAFFER
- Web page: https://patentgrep.com/patent/US20180021265A1

## CPC

- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61P 35/00: Antineoplastic agents
- A61K 31/195: having an amino group
- A61K 31/7028: Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Methods and compositions described herein use polysaccharide nanoparticles (or polysaccharide-coated nanoparticles) to retain and deliver unaltered therapeutic agents to sites of disease. The polysaccharide nanoparticles are non-covalently associated with the unaltered therapeutic agent. The polysaccharide is able to retain cargo (drugs, diagnostics, etc.) without chemical modification of the agent. The nanoparticle maintains its association with the agent through non-covalent interactions but releases its agent in response to changes in the microenvironment, e.g., at the site of cancer cells or cancer tissue.

## Claims

### Claim 1

A method of delivering one or more agents to a site in a subject, the method comprising:
administering a nanoparticle composition comprising:
one or more unaltered agents associated with nanoparticles comprising a polysaccharide wherein an intensity-weighted average diameter of the nanoparticles as determined by dynamic light scattering is from 1 nm to 500 nm.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein the nanoparticles are at least 50 wt. % polysaccharide (e.g., at least 60 wt. %, at least 70 wt. %, at least 80 wt. %, at least 90 wt. %).

### Claim 4 (depends on 1)

The method of claim 1, wherein each of the nanoparticles have a surface comprising the polysaccharide.

### Claim at position 5

5-6. (canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the polysaccharide comprises a member selected from the group consisting of dextran, amylose, amylopectin, glycogen, cellulose, arabonixylan, and pectin.

### Claim 8 (depends on 1)

The method of claim 1, wherein the disease, disorder, or condition is a member selected from the group consisting of cancer, rheumatoid arthritis, atherosclerosis, cystic fibrosis, diabetic ketoacidosis, cardiac arrest, stroke, renal failure, malaria, lactic acid acidosis, and inflammation.

### Claim at position 8

9-22. (canceled)

### Claim 23

A composition comprising:
one or more unaltered agents associated with nanoparticles comprising a polysaccharide wherein an intensity-weighted average diameter of the nanoparticles as determined by dynamic light scattering is from 1 nm to 500 nm.

### Claim 24

(canceled)

### Claim 25 (depends on 23)

The composition of claim 23, wherein the one or more unaltered agents comprise a chemotherapy drug.

### Claim 26 (depends on 25)

The composition of claim 25, wherein the chemotherapy drug is a member selected from the group consisting of doxorubicin, amphotericin B, daunarubicine, cytarabine, enzalutamide, methotrexate, cytarabine, gemcitabine, decitabine, azacitidine, fludarabine, nelarabine, cladribine, clofarabine, pentostatin, thioguanine, mercaptopurine, photosensitizer (photodynamic therapy agent), biologic, including peptides and peptidomimetics, kinase inhibitors, and a combination of any two or more thereof.

### Claim 27 (depends on 25)

The composition of claim 25, wherein the chemotherapy drug is doxorubicin.

### Claim 28

(canceled)

### Claim 29 (depends on 23)

The composition of claim 23, wherein the one or more unaltered agents comprise an imaging agent.

### Claim 30 (depends on 23)

The composition of claim 23, wherein the composition comprises at least one therapeutic agent and at least one imaging agent associated with the nanoparticles.

### Claim 31 (depends on 23)

The composition of claim 23, wherein the polysaccharide is a member selected from the group consisting of dextran, amylose, amylopectin, glycogen, cellulose, arabonixylan, and pectin.

### Claim 32 (depends on 31)

The composition of claim 31, wherein the polysaccharide is an unsubstituted dextran.

### Claim 33 (depends on 23)

The composition of claim 23, wherein the nanoparticles have an intensity-weighted average diameter of at least 5 nm.

### Claim 34 (depends on 23)

The composition of claim 23, wherein the nanoparticles have an intensity-weighted average diameter between 15 nm and 200 nm.

### Claim 35 (depends on 23)

The composition of claim 23, wherein the nanoparticles do not have a crystalline core, or a metalloid oxide core).

### Claim 36 (depends on 23)

The composition of claim 23, wherein the nanoparticles do not contain iron.

### Claim 37 (depends on 23)

The composition of claim 23, further comprising a carrier.

### Claim at position 24

38-66. (canceled)

### Claim 67 (depends on 23)

The composition of claim 23, wherein the nanoparticles comprise at least 50 wt. % polysaccharide.

### Claim 68 (depends on 23)

The composition of claim 23, wherein each of the nanoparticles comprise a surface comprising the polysaccharide.